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Summary
Background Early reports on patients with cancer and COVID-19 have suggested a high mortality rate compared with 
the general population. Patients with thoracic malignancies are thought to be particularly susceptible to COVID-19 given 
their older age, smoking habits, and pre-existing cardiopulmonary comorbidities, in addition to cancer treatments. 
We aimed to study the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients 
with thoracic malignancies.
Methods The Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry is a multicentre 
observational study composed of a cross-sectional component and a longitudinal cohort component. Eligibility criteria 
were the presence of any thoracic cancer (non-small-cell lung cancer [NSCLC], small-cell lung cancer, mesothelioma, 
thymic epithelial tumours, and other pulmonary neuroendocrine neoplasms) and a COVID-19 diagnosis, either 
laboratory confirmed with RT-PCR, suspected with symptoms and contacts, or radiologically suspected cases with lung 
imaging features consistent with COVID-19 pneumonia and symptoms. Patients of any age, sex, histology, or stage 
were considered eligible, including those in active treatment and clinical follow-up. Clinical data were extracted from 
medical records of consecutive patients from Jan 1, 2020, and will be collected until the end of pandemic declared by 
WHO. Data on demographics, oncological history and comorbidities, COVID-19 diagnosis, and course of illness and 
clinical outcomes were collected. Associations between demographic or clinical characteristics and outcomes were 
measured with odds ratios (ORs) with 95% CIs using univariable and multivariable logistic regression, with sex, age, 
smoking status, hypertension, and chronic obstructive pulmonary disease included in multivariable analysis. This is a 
preliminary analysis of the first 200 patients. The registry continues to accept new sites and patient data.
Findings Between March 26 and April 12, 2020, 200 patients with COVID-19 and thoracic cancers from eight countries 
were identified and included in the TERAVOLT registry; median age was 68·0 years (61·8–75·0) and the majority had 
an Eastern Cooperative Oncology Group performance status of 0–1 (142 [72%] of 196 patients), were current or former 
smokers (159 [81%] of 196), had non-small-cell lung cancer (151 [76%] of 200), and were on therapy at the time of 
COVID-19 diagnosis (147 [74%] of 199), with 112 (57%) of 197 on first-line treatment. 152 (76%) patients were 
hospitalised and 66 (33%) died. 13 (10%) of 134 patients who met criteria for ICU admission were admitted to ICU; 
the remaining 121 were hospitalised, but were not admitted to ICU. Univariable analyses revealed that being older 
than 65 years (OR 1·88, 95% 1·00–3·62), being a current or former smoker (4·24, 1·70–12·95), receiving treatment 
with chemotherapy alone (2·54, 1·09–6·11), and the presence of any comorbidities (2·65, 1·09–7·46) were associated 
with increased risk of death. However, in multivariable analysis, only smoking history (OR 3·18, 95% CI 1·11–9·06) 
was associated with increased risk of death.
Interpretation With an ongoing global pandemic of COVID-19, our data suggest high mortality and low admission to 
intensive care in patients with thoracic cancer. Whether mortality could be reduced with treatment in intensive care 
remains to be determined. With improved cancer therapeutic options, access to intensive care should be discussed in 
a multidisciplinary setting based on cancer specific mortality and patients’ preference.
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Introduction
COVID-19, a respiratory tract infection caused by the 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), emerged in Wuhan, China, in late 2019.1 
Its rapid global spread led WHO to declare a pandemic 
in early March, 2020,2 with more than 7 360 200 confirmed 
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cases and 416 000 deaths as of June 11.3 Due to limited 
testing capacity, the true global infection and mortality 
rates are likely to far exceed the confirmed cases.4
One of the first publications describing patients infected 
with SARS-CoV-2 came from The National Health 
Commission of China and reported on 1099 patients 
from 552 hospitals.5 They noted that 24% of patients had 
comorbidities associated with a more severe SARS-CoV-2 
infection. In patients admitted to hospital, the median 
duration of hospital stay was 12 days, 5% required an 
admission to the intensive care unit (ICU), 2·3% required 
mechanical ventilation and 1·4% died. The most common 
presenting symptoms at time of hospital admission were 
cough and fever. In the largest report from Italy on 
1591 patients with COVID-19 admitted to the ICU, 
88% required mechanical venti lation and 68% had at 
least one comorbidity, with hyper tension in 49% of 
patients.6 At the time of publication, 16% of patients had 
been discharged and 26% had died, with age being the 
most significant risk factor for mortality. Many other 
reports describe similar clinical features of patients 
presenting with COVID-19.7–11 The differences in patients’ 
demographics and mortality between the reports from 
China and those from Italy and other countries have not 
yet been fully explained. Data on how the virus affects 
patients living with cancer has also emerged. A report of 
1524 patients with cancer who were screened at Zhongnan 
Hospital in Wuhan identified COVID-19 in 12 (0·8%) 
patients, seven of whom had non-small-cell lung cancer 
(NSCLC) and more than half of whom were on active 
therapy. One patient required ICU admission and three 
patients died, leading the authors to conclude that 
patients with cancer had a higher risk of mortality 
compared with the community.12 A second report from 
Wuhan on 1590 hospitalised patients with COVID-19 
noted a higher incidence and risk for ICU admission or 
mortality in patients with cancer.13 These publications are 
limited by their small sample size and the inherent bias 
that patients with cancer were more likely to be tested for 
the virus by nature of their symptoms and frequency of 
contacts with the medical system.14,15
In a recent commentary, Lipsitch and colleagues posed 
several important questions that need to be answered to 
characterise the impact of this new virus on patients, 
including elucidating the full spectrum of the disease, 
ranging from asymptomatic to fatal.16 They also emp-
hasised the need to identify subgroups most likely to have 
poor outcomes, thereby deserving specific prev ention and 
therapy efforts.16 Many scientific societies have provided 
clinical recommendations for the manage ment of pat-
ients with cancer, revisiting standards of care and allowing 
for a better risk–benefit ratio in this period of rapid viral 
circulation, including minimising hospital visits, which 
have been identified as a contamination risk.17,18 Regarding 
systemic treatments, a particular emphasis has been 
placed on immune check point inhibitors, which have 
been assumed to result in more complications in patients 
who are infected with SARS-CoV-2, albeit without any 
reliable scientific evidence.19
Unfortunately, epidemiological data suggest that the 
pandemic will continue for months if not for years.20 The 
improvement in lung cancer mortality reported in 2020 
is thought to be due to major advances in the treatment 
of patients with advanced-stage NSCLC, who are treated 
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Evidence before this study
We searched PubMed on March 16, 2020, using the search terms 
(“novel coronavirus” OR “SARS-CoV-2” OR “COVID-19”) AND 
(“cancer” OR “carcinoma” OR “tumor” OR “thoracic cancer” OR 
“NSCLC” OR “lung cancer”) for articles in English that documented 
the risk factors for morbidity and mortality from COVID-19 in 
patients with and without cancer. Data on the impact of severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection 
on patients with cancer is scant and predominantly from 
retrospective series emerging from China. Although previous 
reports on patients with cancer infected with SARS-CoV-2 have 
suggested a higher mortality rate compared with the general 
population, the applicability of such data is hampered by small 
sample sizes, including 1–2% of the total patient population with 
multiple different tumour types, at a single institution. Among 
them, patients with thoracic malignancies are thought to be 
particularly vulnerable.
Added value of this study
To our knowledge, this is the first report of the effect of 
SARS-CoV-2 infection on patients with thoracic cancers, using 
a global database (TERAVOLT) that aims to understand the 
effect of SARS-CoV-2 infection on this patient group. To date, 
we have obtained data from 200 patients with thoracic cancers 
in eight countries, predominantly in Europe, with most 
patients on active treatment at the time of infection. We report 
a 33% mortality rate and a low proportion of patients receiving 
intensive care or mechanical ventilation. Only smoking seems 
to significantly correlate with higher death rates.
Implications of all the available evidence
Overall, patients with thoracic malignancies have a higher 
mortality compared with that reported for the general 
population, in line with previous reports from China. As most 
patients were on therapies that have been shown to improve 
survival at the time of SARS-CoV-2 infection, a diagnosis of 
thoracic malignancy alone should not be an exclusion criteria 
for ICU admission and care. Also, the effect of smoking—both 
former and current—should be further investigated. TERAVOLT 
will continue to register patients to identify those with higher 
risk of severe SARS-CoV-2 infection and the effect of specific 
COVID-19 therapies on outcomes.
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with tyrosine kinase inhibitors (TKIs) and immune 
checkpoint inhibitors.21 The fear and anxiety created by 
the outbreak of COVID-19 has resulted in a major shift in 
cancer care delivery, with hospitals reducing patient visits 
and implementing telemedicine while delaying surgery, 
systemic therapy, and routine follow-up. Screening rates 
allowing for earlier detection of cancers have also 
undoubtedly dropped as many health-care systems have 
postponed elective imaging procedures, as has been 
dramatically observed for breast, colon, and cervical 
cancer screenings.22 While such strict measures are 
necessary in the short term to protect patients from 
SARS-CoV-2 infection, prolonged treatment delays could 
lead to an increase in cancer-related mortality. There-
fore, it is crucial to understand the impact of COVID-19 
on patients with cancer to ensure optimal care. The 
Thoracic Cancers International COVID-19 Collaboration 
(TERAVOLT) is the first global registry aimed at under-
standing the effect of SARS-CoV-2 infection on patients 
with thoracic malignancies.
Methods
Study design and participants
This study is composed of a cross-sectional component 
and a longitudinal cohort component. The cross-sectional 
part describes the patients and disease characteristics 
both for cancer and for COVID-19 disease, including 
treatment received and complications due to therapy; the 
longitudinal component is related to the association 
between potential prognostic factors and outcome.
Institutions from around the world were invited via 
email to collaborate. Almost 200 centres have expressed 
interest in collaborating on the database; to date, 87 have 
received Institutional Review Board approval and have 
contributed data (appendix pp 12–13). Main eligibility 
criteria were patients with thoracic cancer (NSCLC, 
small-cell lung cancer, mesothelioma, thymic epithelial 
tumours, and other pulmonary neuroendocrine neo-
plasms) with a COVID-19 diagnosis defined as any of the 
following: lab oratory confirmed (using RT-PCR tech-
niques) COVID-19; sus pected COVID-19 with at least 
one of the following symptoms: fever higher than 
37·5°C, decrease of oxygen saturation of at least 5%, 
cough, diarrhoea, otitis, dysgeusia, myalgia, arthralgia, 
conjunc tivitis, and rhinor rhoea, and, when available, 
known exposure to a person with confirmed COVID-19; 
or radiologically suspected cases with lung imaging 
features consistent with COVID-19 pneumonia and 
symptoms. Asymptomatic patients found positive for 
SARS-CoV-2 were included in this analysis; these 
patients were tested although asymptomatic according 
to local and institu tional policies or owing to known 
exposure to a person with confirmed COVID-19. Patients 
of any age, sex, histology, or stage were considered 
eligible, including those in active treatment and clinical 
follow-up. Full eligibility criteria are listed in the study 
protocol (appendix pp 14–20). Participating centres were 
asked to enrol consecutive patients with these char ac-
teristics.
Local Institutional Review Board approval is required 
for each centre before data entry. For those institutions 
that required consent, when possible written informed 
consent was obtained. A waiver was allowed for those 
who were not able to sign. All study procedures were in 
accordance with the precepts of Good Clinical Practice 
and the declaration of Helsinki. According to the 
regulation (EU) 2016/679 of the European Parliament 
and of the Council of April 27, 2016, the following 
require ments regarding personal data were guaranteed: 
pseudony misation and encryption, confidentiality, inte-
grity, availa bility, resilience of treatment systems and 
services, and the ability to restore the availability and 
access of data in the event of a physical or technical 
accident.
Procedures
Data are entered into a de-identified REDCap (Research 
Electronic Data Capture) database, with each institution 
assigned a unique number. REDCap is a secure web 
platSform for building and managing online databases 
and surveys; it provides easy data handling (with audit 
trails for reporting, monitoring, and querying patient 
records) and an automated export mechanism to common 
statistical packages (SPSS, SAS, Stata, R/S-Plus).
Clinical data were extracted from medical records of 
consecutive patients from Jan 1, 2020, and will be 
collected until the end of pandemic declared by WHO. 
Data are divided into four main categories: demographics, 
oncological history and comorbidities, COVID-19 diag-
nosis, and course of illness and clinical outcomes 
(appendix p 2). Oncological outcomes will be collected 
until the end of the study for all patients included to 
evaluate the effect of this pandemic on treatment delays. 
Initial case report form variables were chosen according 
to available data from the literature and are updated on 
the basis of emerging evidence.23
Basic demographic characteristics, including age, sex, 
smoking status, race, stage of disease at COVID-19 
diagnosis (American Joint Committee on Cancer clinical 
stages), type of thoracic malignancy, current oncological 
treatment, comorbidities, concomitant medications, 
method for COVID-19 diag nosis, and need for hospital 
admission, were recorded; a complete list can be found 
in the appendix (p 2). For hospitalised patients, the 
length of hospital stay and need for admission to ICU 
were also recorded. Criteria for ICU admission were 
defined as needing a higher level of care including more 
intense monitoring, ventilation, and resuscitation.
Statistical analysis
Descriptive statistics of patients’ demographics (eg, age, 
sex) and clinical characteristics (eg, comorbidities, severe 
events, therapy) were reported as frequencies (propor-
tions) for categorical variables and median (IQR) for 
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continuous variables. Summary measures for asso cia tion 
between demographic and clinical characteristics and 
outcomes (hospital isation, prolonged hos pital isation 
[>8 days], and death) were assessed by univariable logistic 
models; the association with risk of death was also 
assessed with multivariable logistic models. Results are 
given as odds ratios (ORs) with 95% CIs. In multivariable 
analysis of factors associated with risk of death, we 
included sex, age (>65 years vs ≤65 years), smoking status 
(current or former vs never), hypertension, and chronic 
obstructive pulmonary disease (COPD)—all factors 
known from the literature to be associated with COVID-19 
outcomes in general patient populations. Patients with 
missing values were excluded from univariable and 
multivariable anal yses. All analyses were done using R 
(version 3.6).
No power analysis was done to calculate the sample 
size, and the aim was descriptive in nature, focusing on 
estimation rather than hypothesis testing. With about 
150 centres contributing data and about five patients 
from every centre, a sample size of approximately 
750 patients can produce a CI of ±2% for estimates of 
proportion. In this study, we present preliminary data on 
the first 200 consecutive patients enrolled; the cutoff 
number was not dependent on previous knowledge of 
results but was driven by the emergency and the lack of 
data provided in this setting so far. This report of the first 
200 patients was not prespecified in the protocol but was 
written to disseminate information quickly during the 
pandemic. With a CI of less than 14%, we believe the 
results can assure a reasonably precise preliminary 
estimate for the purpose of our study.
Role of the funding source
There was no funding source for this study. The corres-
ponding author had full access to all of the data and the 
final responsibility to submit for publication.
Results
Between March 26 and April 12, 2020, data on the first 
200 patients were entered into the TERAVOLT registry, 
from 42 institutions across eight countries (Italy, Spain, 
France, Switzerland, Netherlands, USA, UK, and China).
180 (91%) of the 198 patients with COVID-19 diagnosis 
information were diagnosed with COVID-19 by RT-PCR, 
five (3%) were diagnosed on the basis of clinical 
symptoms (with fever >37·5°C [n=4] and dyspnoea [n=4] 
in most patients), and 13 (7%) had radiological find ings 
that were highly suggestive of COVID-19. The remaining 
two patients were missing data on COVID-19 diagnostic 
tests. Median follow-up since COVID-19 diagnosis was 
15 days (IQR 8–24). Median age was 68·0 years 
(61·8–75·0). The majority of patients were male, white, 
or current or former smokers (table 1). The most com-
mon histology was NSCLC, followed by small-cell lung 
cancer. Most patients had stage IV disease, and 147 (74%) 
patients were currently undergoing treatment, of whom 
144 were receiving systemic therapy (table 1). The 
most common treatments were chemotherapy alone, 
immune checkpoint inhibitors alone, TKIs alone, and 
chemotherapy in combination with immune checkpoint 
All patients (n=200) Hospitalised (n=152) Not hospitalised 
(n=48)
Age, years 68·0 (61·8–75·0) 68·5 (62·0–75·2) 66·0 (59·0–71·5)
<50 12 (6%) 8 (5%) 4 (8%)
50–65 66 (33%) 47 (31%) 19 (40%)
>65 122 (61%) 97 (64%) 25 (52%)
Sex
Female 59 (30%) 42 (28%) 17 (35%)
Male 141 (70%) 110 (72%) 31 (65%)
Smoking status
Current 48/196 (24%) 38/148 (26%) 10 (21%)
Former 111/196 (57%) 84/148 (57%) 27 (56%)
Never 37/196 (19%) 26/148 (18%) 11 (23%)
Race
White 184/195 (94%) 142/149 (95%) 42/46 (91%)
Other 11/195 (6%) 7/149 (5%) 4/46 (9%)
Region
Europe 196 (98%) 149 (98%) 47 (98%)
USA 3 (2%) 2 (1%) 1 (2%)
Asia 1 (1%) 1 (1%) 0
Country
Italy 118 (59%) 86 (57%) 34 (71%)
Spain 36 (18%) 34 (22%) 2 (4%)
France 26 (13%) 19 (12%) 7 (15%)
Switzerland 8 (4%) 5 (3%) 3 (6%)
Netherlands 6 (3%) 5 (3%) 1 (2%)
USA 3 (2%) 2 (1%) 1 (2%)
UK 2 (1%) 1 (1%) 1 (2%)
China 1 (1%) 1 (1%) 0
Cancer stage at COVID-19 diagnosis
I 15 (8%) 11 (7%) 4 (8%)
II 2 (1%) 2 (1%) 0
III 36 (18%) 28 (18%) 8 (17%)
IV 147 (74%) 111 (73%) 36 (75%)
Cancer diagnosis
NSCLC 151 (76%) 111 (73%) 40 (83%)
Small-cell lung cancer 29 (15%) 23 (15%) 6 (13%)
Thymoma or thymic carcinoma 8 (4%) 7 (5%) 1 (2%)
Carcinoid or neuroendocrine 4 (2%) 3 (2%) 1 (2%)
Malignant pleural mesothelioma 8 (4%) 8 (5%) 0
ECOG performance status
0 63/196 (32%) 63/196 (32%) 63/196 (32%)
1 79/196 (40%) 79/196 (40%) 79/196 (40%)
2 35/196 (18%) 35/196 (18%) 35/196 (18%)
3 16/196 (8%) 16/196 (8%) 16/196 (8%)
4 3/196 (2%) 3/196 (2%) 3/196 (2%)
Currently undergoing treatment
Yes 147/199 (74%) 106/151 (70%) 41 (85%)
No 52/199 (26%) 45/151 (30%) 7 (15%)
(Table 1 continues on next page)
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inhibitors; the majority of patients were on first-line 
treatment with therapy administered a median of 7 days 
(IQR 0–17) before COVID-19 diagnosis (table 1). 32 (16%) 
of 198 patients had no comorbidities; in those with 
comorbidities, the most common were hypertension and 
COPD (table 1). 50 (26%) of 195 patients were on 
anticoagulants and 42 (22%) were on steroids (table 1).
The most common presenting symptoms were fever, 
dyspnoea, and cough (table 2). There were a median of 
5 days (IQR 2–7) between onset of symptoms and 
diagnosis and a median 7 days (2–13) of hospitalisation. 
Of 200 patients, 143 had developed complications by 
April 12, 2020, with 92 (46%) patients still hospitalised 
at the time of data cutoff. The most common com-
plications were pneumonia or pneumonitis and acute 
respiratory distress syndrome (table 2). 24 (12%) of 
198 patients were asymptomatic; 13 (54%) of these 
patients were tested in hospitals due to known exposure 
to a patient with confirmed SARS-CoV-2 infection, 
whereas six (25%) had secondary findings on routine 
imaging for anti cancer therapy or surveillance; details 
on the remaining five patients are unknown.
Of the 152 hospitalised patients, 134 (88%) met criteria 
for ICU admission, but only 13 (10%) of these patients 
were admitted to the ICU, nine of whom were mechani-
cally ventilated (table 3). Predominantly, the reasons for 
patients not being admitted to ICU was reported as not 
indicated, which included institutional policy against ICU 
admis sion, underlying cancer diagnosis and decision not 
to escalate to ICU, or not indicated due to severity of 
COVID-19 illness and physician recommen dation not to 
escalate to ICU for futility in patients with advanced-stage 
cancer; only six (5%) of 114 patients with data available 
that were offered ICU-level care declined ICU admission 
(table 3). 31 (53%) of 58 hospitalised patients with data on 
complete length of stay had a prolonged hospital isation, 
defined as longer than 8 days. Of the 66 (33%) patients 
who died, 52 (79%) deaths were listed as due to 
complications from COVID-19 only, seven (11%) as cancer 
progression only, three (5%) as compli cations from 
COVID-19 and cancer progression, one (2%) as compli-
cations from cancer therapy, one (2%) as cancer 
progression and other reasons, and one (2%) as other 
reasons. Cause of death for one patient was not listed. 
52 (79%) patients died in hospital, eight died in the ICU 
(12%), and three (5%) died at home; details are unknown 
for the three (5%) remaining deaths.
Univariable analyses revealed that being older than 
65 years (OR 1·88, 95% 1·00–3·62), being a current or 
former smoker (4·24, 1·70–12·95), receiving treatment 
with chemotherapy alone (2·54, 1·09–6·11), and the 
presence of any comorbidities (2·65, 1·09–7·46) were 
associated with increased risk of death. Dyspnoea was 
also associated with increased risk of death (6·20, 
3·10–13·23), whereas experiencing no symptoms at the 
time of diagnosis was associated with decreased risk 
(0·08, 0·00–0·38; appendix pp 3–7). Although the 
All patients (n=200) Hospitalised (n=152) Not hospitalised 
(n=48)
(Continued from previous page)
Line of therapy
0 42/197 (21%) 37/149 (25%) 5 (10%)
1 112/197 (57%) 78/149 (52%) 34 (71%)
2 25/197 (13%) 21/149 (14%) 4 (8%)
≥3 18/197 (9%) 13/149 (9%) 5 (10%)
Current therapy
TKI alone 28/147 (19%) 17/106 (16%) 11/41 (27%)
Chemotherapy alone 48/147 (33%) 35/106 (33%) 13/41 (32%)
Immune checkpoint 
inhibitors alone
34/147 (23%) 26/106 (25%) 8/41 (20%)
Chemotherapy and immune 
checkpoint inhibitors
20/147 (14%) 16/106 (15%) 4/41 (10%)
Other* 17/147 (12%) 12/106 (11%) 5/41 (12%)
Comorbidities
Any 166/198 (84%) 134/151 (89%) 32/47 (68%)
Autoimmune disease 6/198 (3%) 6/151 (4%) 0/47
Chronic hepatitis 3/198 (2%) 2/151 (1%) 1/47 (2%)
Chronic kidney insufficiency 15/198 (8%) 13/151 (9%) 2/47 (4%)
COPD 51/198 (26%) 44/151 (29%) 7/47 (15%)
Diabetes 29/198 (15%) 20/151 (13%) 9/47 (19%)
Hypertension 93/198 (47%) 76/151 (50%) 17/47 (36%)
Lung fibrosis 3/198 (2%) 3/151 (2%) 0/47
History of cerebrovascular disease 10/198 (5%) 8/151 (5%) 2/47 (4%)
History of ischaemic heart disease 30/198 (15%) 23/151 (15%) 7/47 (15%)
History of tuberculosis 3/198 (2%) 3/151 (2%) 0/47
History of viral hepatitis B 8/198 (4%) 6/151 (4%) 2/47 (4%)
History of viral hepatitis C 5/198 (3%) 5/151 (3%) 0/47
Other 93/198 (47%) 77/151 (51%) 16/47 (34%)
Number of comorbidities
None 32/198 (16%) 17/151 (11%) 15/47 (32%)
1 60/198 (30%) 44/151 (29%) 16/47 (34%)
2 53/198 (27%) 45/151 (30%) 8/47 (17%)
≥3 53/198 (27%) 45/151 (30%) 8/47 (17%)
Concomitant medications
ACE inhibitors 30/195 (15%) 23/148 (16%) 7/47 (15%)
Angiotensin II receptor blockers 25/195 (13%) 21/148 (14%) 4/47 (9%)
NSAID 2/195 (1%) 1/148 (1%) 1/47 (2%)
Steroids (>10 mg of prednisone) 42/195 (22%) 31/148 (21%) 11/47 (23%)
Immunosuppressive drugs 2/195 (1%) 2/148 (1%) 0/47
Aspirin 39/195 (20%) 30/148 (20%) 9/47 (19%)
Anticoagulants 50/195 (26%) 42/148 (28%) 8/47 (17%)
Other chronic therapy 98/195 (50%) 76/148 (51%) 22/47 (47%)
None 35/195 (18%) 25/148 (17%) 10/47 (21%)
Data are n (%), n/N (%), or median (IQR). NSCLC=non-small-cell lung cancer. ECOG=Eastern Cooperative Oncology 
Group. TKI=tyrosine kinase inhibitor. COPD=chronic obstructive pulmonary disease. NSAID=non-steroidal 
anti-inflammatory drug. ACE=angiotensin-converting enzyme. *Other includes additional combinations of treatment 
modalities: chemotherapy, immune checkpoint inhibitors, and radiotherapy (n=2); chemotherapy and radiotherapy 
(n=6); immune checkpoint inhibitors and cementoplasty (n=1); immune checkpoint inhibitors and other unknown 
(n=1); radiotherapy (n=3); TKI and chemotherapy (n=1); TKI, chemotherapy, and immune checkpoint inhibitors (n=1); 
TKI, chemotherapy, immune checkpoint inhibitors, and radiotherapy (n=1); and TKI and radiotherapy (n=1).
Table 1: Demographic and clinical characteristics
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number of patients is small (n=28), patients treated with 
TKIs alone were less likely to be hospitalised (0·24, 
0·08–0·71) than patients not on therapy, whereas patients 
with fever (2·46, 1·27–4·80) and dyspnoea (2·66, 
1·37–5·32) were more likely to be hospitalised, as were 
patients with any comorbities (3·70, 1·66–8·21), inclu-
ding COPD (2·35, 1·03–6·09). Full univariable anal yses 
for the risk of hospitalisation, prolonged hospital isation, 
and death are in the appendix (pp 3–7). In multivariable 
analysis for risk of death, only smoking history (3·18, 
1·11–9·06) was associated with increased risk of death 
(table 4).
Discussion
TERAVOLT is a global consortium that was formed to 
characterise the effects of SARS-CoV-2 infection on 
patients with thoracic cancers. Our initial report from the 
first 200 patients entered into the registry suggests that 
the mortality in patients with thoracic cancer is 33%, and 
might be as high as previously reported for patients in 
China.12–13,17 In multivariable analysis, only smoking 
habits maintained a significant association with death. 
Comorbidities such as hypertension or ischaemic heart 
disease, which are associated with increased risk of 
death in the general population, did not appear to be 
predictors for poor outcomes in our patient population. 
The question as to whether smoking exacerbated the 
effect of other clinically associated variables (such as 
COPD and other comorbidities) or there is a net effect of 
smoking merits further investigation. However, these are 
preliminary data and we acknowledge that more events 
are needed to observe and confirm effects.
While most deaths occurred during hospital isation, 
only 13 (9%) of 147 patients in our cohort were admitted 
to the ICU, nine of whom received mechanical venti-
lation. This is in contrast with previous reports in which 
16% of hospitalised patients were cared for in the ICU, 
88% of whom received endotracheal intubation and 
mechanical ventilation,6 as well as a report from New 
York City (NY, USA) showing that patients with all types 
of cancer were frequently intubated for COVID-19 treat-
ment.24 Part of this could be explained by the geographical 
locations included in this initial cohort, which were 
mainly European (Italy, France, and Spain). All of these 
regions were par ticularly hard hit and they have universal 
health systems that might differ from other countries. In 
addition, our database includes hetero geneity among 
types of hospitals (comprehensive cancer centres and 
general hospitals).
We tried to capture the reasons for the low rate of ICU 
admission. Difficult decisions were made limiting ICU 
admissions for patients with cancer and others with 
terminal illness due to equipment and personnel short-
ages. However, we are aware that behind these choices 
there might also be patients’ decisions and cultural and 
institutional choices that our work is unable to properly 
capture. Given that our database is longi tudinal, future 
reports from TERAVOLT will evaluate the effect of 
SARS-CoV-2 infection outcomes on patients in hospital 
systems that are not under as much as stress. Nonetheless, 
as targeted therapy and immuno therapy have dramatically 
shifted the paradigm of care and life expectancy for 
patients with metastatic NSCLC, the decision to escalate 
care should be decided in a multi disciplinary setting and 
not on the basis of old pre conceptions limiting access to 
aggressive care for these patients.
Importantly, our data suggest that the type of systemic 
therapy, including TKIs, chemotherapy, and immuno-
therapy, did not affect survival in patients with COVID-19. 
Although the number of patients is small, patients 
treated with TKIs alone were at decreased risk for 
hospitalisation, and despite initial concerns of increased 
mortality, immuno therapy did not worsen outcomes for 





Fever (>37·5°C) 127/198 (64%) 104/150 (69%) 23 (48%)
Dyspnoea 106/198 (54%) 89/150 (59%) 17 (35%)
Cough 103/198 (52%) 83/150 (55%) 20 (42%)
Fatigue 54/198 (27%) 46/150 (31%) 8 (17%)
Headache 13/198 (7%) 10/150 (7%) 3 (6%)
Diarrhoea 10/198 (5%) 10/150 (7%) 0
Myalgia 10/198 (5%) 9/150 (6%) 1 (2%)
Nasal congestion 6/198 (3%) 5/150 (3%) 1 (2%)
Anosmia* 7/198 (4%) 4/150 (3%) 3 (6%)
Dysgeusia 7/198 (4%) 4/150 (3%) 3 (6%)
Loss of smell or taste* 6/198 (3%) 4/150 (3%) 2 (4%)
Shivers 4/198 (2%) 4/150 (3%) 0
Conjunctival congestion 1/198 (1%) 0/150 1 (2%)
Otitis 0/198 0/150 0
Other 19/198 (10%) 17/150 (11%) 2 (4%)
None (asymptomatic) 24/198 (12%) 9/150 (6%) 15 (31%)
Diagnostic test
RT-PCR 180/198 (91%) 140/150 (93%) 40 (83%)
Clinical findings 5/198 (3%) 2/150 (1%) 3 (6%)
Radiological findings 13/198 (7%) 8/150 (5%) 5 (11%)
Complications
Any complications 143/157 (91%) 123/127 (97%) 20/30 (67%)
Pneumonia or pneumonitis 125/157 (80%) 90/127 (71%) 16/30 (53%)
Acute respiratory distress syndrome 42/157 (27%) 40/127 (31%) 2/30 (7%)
Multi-organ failure 12/157 (8%) 11/127 (9%) 1/30 (3%)
Sepsis 8/157 (5%) 7/127 (6%) 1/30 (3%)
Coagulopathy 8/157 (5%) 8/127 (6%) 0/30
Bacterial infection 6/157 (4%) 6/127 (5%) 0/30
Arrhythmia 3/157 (2%) 3/127 (2%) 0/30
Heart failure 1/157 (1%) 1/127 (1%) 0/30
Other 15/157 (10%) 12/127 (9%) 3/30 (10%)
No complications 14/157 (9%) 4/127 (3%) 10/30 (33%)
*Data obtained as two separate questions.
Table 2: COVID-19 clinical presentation and symptoms
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patients with cancer with COVID-19 in our analysis. 
These findings suggest that withholding or discontinuing 
such therapy for a patient out of fear of COVID-19 might 
not be warranted. We note, however, that more data with 
larger patient numbers are needed to make a final verdict 
on the role of treatments. Moreover, it is important to 
acknowledge that previous studies have suggested that 
frequent contact with the health-care environment 
increases risk of SARS-CoV-2 infection and thus a goal of 
minimising such contact, especially during cancer 
therapy, is important.7,17
The most common presenting symptoms for patients 
with thoracic cancer and COVID-19 are also those 
symptoms frequently noted by patients with thoracic 
cancer without COVID-19, including dyspnoea, cough, 
and fatigue. However, very few patients died due to 
progressive disease, with most dying of complications of 
COVID-19 itself. Furthermore, the majority of our 
patients had a stage IV disease (74%) and a large prop-
ortion were on active oncological treatment (74%) at the 
time of SARS-CoV-2 infection; in particular, 57% of 
patients were on first line with therapy administered a 
median of 7 days before COVID-19 diagnosis. The 
patients included in this analysis could represent a 
selected pop ulation since this initial cohort did not 
capture many patients after surgery or radiotherapy; 
efforts will be made to expand TERAVOLT participation 
beyond med ical oncologists to include other thoracic 
cancer disciplines (eg, thoracic surgeons and radiation 
oncologists). Furthermore, we recognise that this is a 
preliminary report, written to provide more infor mation 
to clinicians at a crucial time, but that it does not yet have 
the statistical power to give final answers in terms of 
subgroup analyses.
While the data presented here are representative of 
mainly symptomatic patients with NSCLC stage IV 
disease on systemic therapy and importantly only include 
a small fraction of patients who were managed at home 
for their COVID-19 illness, data are urgently needed to 
plan the optimal diagnostic and therapeutic pathways 
for patients with cancer in an environment where 
SARS-CoV-2 is still in circulation, often accompanied 
with only mild or no symptoms. Although consecutive 
inclusion of patients controls the risk of selection bias, 
thus assuring a correct description of patients’ charac-
teristics and outcomes, major limitations in the esti-
mation and correct inter pretation of associations were 
related to control of con founding factors. More data on 
the prevalence and out comes of COVID-19 on asymp-
tomatic patients with thoracic cancer could emerge as 
hospital systems imple ment broader testing on all 
patients seeking care.
TERAVOLT is a unique effort aimed at providing real-
time data to support the optimal diagnostic and thera-
peutic pathways for all patients with thoracic cancer. 
Given our findings suggest a high risk of severe infection 
or death for patients with thoracic malignancies, a 
tailored approach is needed. Calabró and colleagues have 
proposed routine testing for patients with cancer on 
active therapy;25 the continued shortage of testing kits 
and variances across countries makes such an approach 
difficult to achieve universally, but it could indeed be the 
optimal approach once an effective therapy for COVID-19 
has been found. For now, emphasising social distancing 
and encouraging measures such as wearing face masks 
in the community might help to minimise a surge of 
cases, allowing the medical system to keep up with 
testing and decreasing the need for physicians to triage 
care on the basis of age and comor bidities. Protecting all 
Odds ratio (95% CI)
COPD 1·18 (0·59–2·37)
Hypertension 1·16 (0·61–2·21)
Female sex (vs male) 0·69 (0·33–1·44)
Age >65 years (vs ≤65 years) 1·53 (0·77–3·03)
Current or former smoker (vs never smoker) 3·18 (1·11–9·06)
 Outcome includes death during hospitalisation, in the intensive care unit, or at 
home. COPD=chronic obstructive pulmonary disease.











Prolonged hospitalisation (>8 days)†
Yes 31/58 (53%)
No 27/58 (47%)
Death (during hospitalisation, ICU, or at home)‡
Yes 66 (33%)
No 125 (63%)
Reasons why patients were not admitted to the ICU§
Not indicated¶ 97/114 (85%)
No resources available 4/114 (4%)
Institutional policy 7/114 (6%)
Patient declined 6/114 (5%)
ICU=intensive care unit. *Calculated on number of hospitalised patients with data 
on ICU admission. †Calculated on number of hospitalised patients with data on 
complete length of stay. ‡The outcome (dead or alive) is unknown for nine 
patients. §Calculated on number of patients eligible for ICU who were not admitted 
for whom the reason for non-admission was available. ¶Not indicated includes 
several factors: not indicated due to mild or moderate COVID-19 symptoms; not 
indicated due to underlying cancer diagnosis and decision not to escalate to ICU; or 
not indicated due to severity of COVID-19 illness and physician recommendation 
not to escalate to ICU for futility. For the majority of sites, it also included 
institutional policy concerning patients with lung cancer.
Table 3: Hospitalisation and mechanical ventilation use
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susceptible members of our societies with protective 
measures supported by our current knowledge of 
SARS-CoV-2 must remain a priority, while also respecting 
the needs of each indivi dual, including optimal care 
management.
We believe that a multidisciplinary approach to the 
treatment of patients with thoracic cancer and SARS-CoV-2 
infection should consider both the indivi dual cancer-
specific mortality and risk of a morbidity or mortality from 
COVID-19. At this time, it is not clear if intu bation and 
more aggressive care in patients with cancer could improve 
COVID-19-specific survival, or if such an approach would 
simply prolong the process of dying. However, in the 
absence of clear data, the inte gration of patients’ pre-
ferences could provide a benefit, especially in decisions in 
which uncer tainty is high.26 In this perspective, a shared 
decision-making paradigm will allow both patients and 
clinicians to recognise and pursue the option that best fits 
the individual.
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